Dynamic simulations on the mitochondrial fatty acid Beta-oxidation network
© Modre-Osprian et al; licensee BioMed Central Ltd. 2009
Received: 28 July 2008
Accepted: 06 January 2009
Published: 06 January 2009
The oxidation of fatty acids in mitochondria plays an important role in energy metabolism and genetic disorders of this pathway may cause metabolic diseases. Enzyme deficiencies can block the metabolism at defined reactions in the mitochondrion and lead to accumulation of specific substrates causing severe clinical manifestations. Ten of the disorders directly affecting mitochondrial fatty acid oxidation have been well-defined, implicating episodic hypoketotic hypoglycemia provoked by catabolic stress, multiple organ failure, muscle weakness, or hypertrophic cardiomyopathy. Additionally, syndromes of severe maternal illness (HELLP syndrome and AFLP) have been associated with pregnancies carrying a fetus affected by fatty acid oxidation deficiencies. However, little is known about fatty acids kinetics, especially during fasting or exercise when the demand for fatty acid oxidation is increased (catabolic stress).
A computational kinetic network of 64 reactions with 91 compounds and 301 parameters was constructed to study dynamic properties of mitochondrial fatty acid β-oxidation. Various deficiencies of acyl-CoA dehydrogenase were simulated and verified with measured concentrations of indicative metabolites of screened newborns in Middle Europe and South Australia. The simulated accumulation of specific acyl-CoAs according to the investigated enzyme deficiencies are in agreement with experimental data and findings in literature. Investigation of the dynamic properties of the fatty acid β-oxidation reveals that the formation of acetyl-CoA – substrate for energy production – is highly impaired within the first hours of fasting corresponding to the rapid progress to coma within 1–2 hours. LCAD deficiency exhibits the highest accumulation of fatty acids along with marked increase of these substrates during catabolic stress and the lowest production rate of acetyl-CoA. These findings might confirm gestational loss to be the explanation that no human cases of LCAD deficiency have been described.
In summary, this work provides a detailed kinetic model of mitochondrial metabolism with specific focus on fatty acid β-oxidation to simulate and predict the dynamic response of that metabolic network in the context of human disease. Our findings offer insight into the disease process (e.g. rapid progress to coma) and might confirm new explanations (no human cases of LCAD deficiency), which can hardly be obtained from experimental data alone.
Ten of the disorders directly affecting mitochondrial fatty acid oxidation have been well-defined, implicating episodic hypoketotic hypoglycemia provoked by catabolic stress, multiple organ failure, muscle weakness, or hypertrophic cardiomyopathy. Additionally, syndromes of severe maternal illness (HELLP syndrome and AFLP) have been associated with pregnancies carrying a fetus affected by fatty acid oxidation deficiencies. The incidence of one of these disorders, MCAD deficiency (MIM 201450), is 1:14 600 in almost 8.2 million newborns worldwide . In the first years of life this inherited deficiency may become apparent following a prolonged fasting period, sometimes in combination with infection or fever. An acute attack usually features symptoms of lethargy, nausea and vomiting, which rapidly progresses to coma within 1–2 h. Up to 25% of MCAD patients die during their first attack; or suffer permanent brain damage from cerebral edema. The clinical phenotypes of most of the disorders of fatty acid metabolism are very similar .
The introduction of tandem mass spectrometry (MS/MS) for the analysis of plasma acylcarnitines has greatly facilitated the identification of patients with a defect in fatty acid β-oxidation and has unquestionably been the most striking recent advance in newborn screening. Pre-symptomatic diagnosis is important to prevent morbidity as most of the diagnosed defects are treatable and the prognosis is generally favorable [10–12].
Besides statistical model building and data mining based approaches [13–15], computational Systems Biology is essential to combine knowledge of human physiology and pathology starting from genomics, molecular biology, and the environment through the levels of cells, tissues, and organs all the way up to integrated systems behavior. Applying Systems Biology approaches within the context of human health and disease will definitely gain new insights. Eventually, a new discipline – Systems Medicine – will emerge at the interface between Medicine and Systems Biology [16–18]. Higher levels of organization are extremely complex and even models at the cell and subcellular levels are forced to resort to simplifications to minimize modeling and computational complexity [19–21]. Additionally, some parameters and constants for kinetics, binding and concentrations of biomolecules are typically not known, thus reducing the model's ability to respond correctly to dynamic changes in external conditions. A high-quality network of human-specific metabolic pathways including detailed knowledge about all metabolic reactions concerned is essential to design tailored kinetic models for better understanding of human metabolism and its relationship with diseases. While such large networks are used to analyze the global structure or functional connectivity of the network , deterministic and stochastic models are mainly used for simulating specific metabolic pathways as well as regulatory and signaling networks .
To date, little is known about fatty acids kinetics, especially during catabolic stress or exercise when the demand for fatty acid oxidation is increased. Here we introduce a detailed kinetic model of mitochondrial metabolism with specific focus on fatty acid β-oxidation to simulate and predict the dynamic response of that metabolic network toward distinct enzyme deficiencies. The simulation results are compared and validated using experimental data. Finally, the dynamic response to changes in the input to the system representing catabolic stress is simulated and results are interpreted in a biological and clinical context, followed by a discussion on limitations of the model.
Construction and evaluation of kinetic model
The reduced activity of acyl-CoA dehydrogenases leads to a deviation of the total activity as compared to healthy controls (Figure 2B) and, subsequently, to the accumulation of specific acyl-CoAs (Figure 3). For example, the reduced acyl-CoA dehydrogenase activity for fatty acids with carbon chain lengths of 4 and 6 results mainly in an increase of acyl-CoAs with carbon chain length 4 in case of SCAD deficiency. The low enzyme activity in MCAD deficiency at chain lengths of 6 to 12 is reflected by a high concentration of octanoyl-CoA (C8). The model predicts the accumulation of specific acyl-CoAs corresponding to the investigated enzyme deficiencies which are in agreement with findings in the literature .
Relationship between model and experimental data
Acylcarnitine concentrations of screened newborns
healthy controls (n = 590.216)
MCAD deficiency (n = 63)
VLCAD deficiency (n = 5)
MCAD deficiency (n = 13)
VLCAD deficiency (n = 3)
MCADD ratios of model and experimentally derived data
VLCADD ratios of model and experimentally derived data
Responses of the model to dynamic changes
Ratios of simulated acyl-CoA concentrations before and after fasting
The present computer simulation attempts to contribute to a better understanding (explanation) of pathophysiological aspects of a group of hereditary disorders impairing mitochondrial β-oxidation. Several enzymes are involved in mitochondrial fatty acid oxidation. For all of them, genetic defects impairing their function have been described. The availability of modern analytical methods has facilitated newborn screening for these disorders. For the identification of patients with a defect in β-oxidation, acylcarnitines in blood were evaluated showing a characteristic profile depending on the affected enzyme even in asymptomatic stage. We simulated the steady-state concentrations of acyl-CoAs in acyl-CoA dehydrogenase deficiencies and compared the results to acylcarnitine data from screening programs in Middle Europe and South Australia. Results indicate that the overall characteristics of the simulated accumulation of acyl-CoA show good agreement with experimental data and findings in the literature (Figure 3 and Figure 4).
Differences in simulated C16 acyl-CoA and measured C16 acylcarnitine might be caused by the special biological role of C16 acylcarnitine. From a biochemical perspective it is not clearly evident why a decrease of acyl-CoA dehydrogenase activity (Figure 2B) would not impact the concentration of C16 acyl-CoA in the mitochondria, leading to a much higher C16 acyl-CoA than C14 acyl-CoA concentration, which is reflected by the measured acylcarnitines (Table 1). It seems that there is an abundant pool of C16 acylcarnitine in the blood, whose level is almost not affected by mitochondrial fatty acid oxidation deficiencies (as can be seen in Table 1). This might be reasonable, since C16 acylcarnitine is an ester of an important saturated fatty acid, which is involved in several biological processes within the body – it is needed for energy, hormone production, cellular membranes and for organ padding as well as for important signaling and stabilization processes in the body.
Differences in simulated acyl-CoA ratios and measured acylcarnitine ratios shown in Table 2 are mainly given by the relatively small value of the simulated C4 acyl-CoA concentration and the relatively large value of the C12 acyl-CoA concentration. Higher values for C4 and lower values for C12 can be mainly generated by changing the activity of the enzymes for chain length 4 and 12. The problem is that we do not exactly know the total enzyme activity because the enzyme activities are based on data from rat liver mitochondria [3–5] (and not on data from human mitochondria). Additionally, mitochondria from different tissues can show different total acyl-CoA dehydrogenase activity as well as possible residual activities of the deficient enzyme are also changing the total acyl-CoA dehydrogenase activity of the individual patient. This might be supported by the high inter-patient variance of the measured acylcarnitines, which is caused not only by the experimental error but also by the biological variance between patients. For example, for some patient data the C12 acylcarnitine concentration is higher than the C14 acylcarnitine concentration (data are not shown). The discrepancy with C14 and C12 (for the simulation data the C12 ratio is higher than the C14 ratio which was not found in the experimental data) can be considered negligible, because of the small difference between C14 and C12 compared to the strong increase of C8 for MCADD. The ratio C8/C14 is more than 10 fold higher than the ratio C12/C14.
The clinical phenotypes of most of the disorders are very similar. As MCAD deficiency is the most prevalent defect among them we focused our discussion and biochemical interpretation on this particular defect. Nevertheless, the aspects are relevant to the pathogenesis of all fatty acid oxidation defects. Patients with MCAD deficiency are without clinical manifestations until a prolonged fasting period sometimes in combination with infection or fever. As a physiological response to this catabolic stress triacylglycerols from adipose tissue are released and energy production switches from carbohydrate to lipid utilization. In healthy individuals, subsequently ketone body formation by the liver is increased to provide this metabolic fuel for brain and muscles.
The response to catabolic stress in patients with MCAD deficiency shows a marked increase in plasma fatty acids, mitochondrial acylcarnitines and acyl-CoAs. Severe symptoms of lethargy and nausea develop as a consequence of encephalopathy, and patients can become dangerously ill, sometimes before plasma glucose falls to hypoglycemic levels. The progression to severe sickness proceeds within a few hours. Patients often die in the course of the first episode or at least suffer from persistent brain damage. The underlying pathogenetic mechanisms have been poorly understood until now. To simulate the response to fasting we assumed a 20% increase of palmitoyl CoA (C16) and observed significant differences of the calculated metabolic changes in acyl-CoA deficiencies with respect to the healthy controls (Figure 5). One major consequence of the disorder is inadequate ketone body formation to meet tissue energy demands under conditions of fasting and catabolic stress. Our calculations showed that formation of acetyl-CoA – substrate for energy production via the tricarboxylic acid (TCA) cycle and ketogenesis – is impaired (Figure 7). The simulation impressively showed the low production rate of acetyl-CoA within the first hours, which corresponds to the rapid disease progression after onset. In addition, inadequate acetyl-CoA production has secondary effects on flux through the TCA cycle, on regulation of fatty acid oxidation, and on efficiency of gluconeogenesis, which contribute to pathogenesis .
The simulated accumulation of specific acyl-CoAs according to the investigated enzyme deficiencies are in agreement with the accumulation of plasma free fatty acid intermediates, which enter the central nervous system and exert toxic effects, which may explain the observed encephalopathy and cerebral edema. In vitro experiments on cerebral cortex of rats indicate that inhibition of energy metabolism and oxidative stress induction by the accumulating fatty acids may contribute to the pathophysiology of encephalopathy [30, 31].
Although several patients have been found to have VLCAD deficiency, none have been documented with LCAD deficiency . This could arise from either gestational loss due to LCAD deficiency as seen in the mouse model, a failure to recognize LCAD deficiency because the phenotype differs so greatly from other inborn errors of fatty acid metabolism, or absence of disease resulting from LCAD deficiency in humans [33, 34]. The dynamic behavior of the simulation model of LCAD deficiency exhibits the highest accumulation of fatty acids (179-fold of C14 as can be seen in Figure 4) along with marked increase of these substrates during fasting (Figure 5 and Table 4) and the lowest production rate of acetyl-CoA (Figure 7). These findings might confirm gestational loss to be the explanation that no human cases of LCAD deficiency have been described.
Our model can be extended to comprehensively test and study deficiencies of mitochondrial trifunctional protein and β-hydroxy-acyl-CoA dehydrogenase, or other diseases of fatty acid oxidation such as carnitine cycle, electron transfer and ketone synthesis defects. Furthermore, differences in the expression level of the enzymes in different cells and tissues and their consequences on the dynamical behavior of the β-oxidation can be investigated. Future work will incorporate the enzymatic steps for unsaturated fatty acids.
In summary, this work provides a stimulating example for Systems Biology in the context of human disease revealing insights into dynamic properties of complex biochemical networks under the constraints of various disease conditions. As analytical technologies for global and targeted measurements mature, especially with regards to metabolites, new findings and hypothesis can be verified utilizing quantitative data. Furthermore, while mitochondrial deficiencies are often treated with metabolites to stimulate the enzyme activities, models will allow evaluation of the influences of metabolite treatments at the mitochondrial level, visualization of the dynamic behavior of the pathway and exploration of a hypothetical rationale of the treatment. In this respect, computational biology proves to be able to uncover insights, which can hardly be obtained from experimental data alone.
The computational model for mitochondrial β-oxidation was based on a publicly available E-Cell2  simulation model developed by Yugi and Tomita . The latter is a computational model of mitochondrial metabolism representative of the entire organelle. We chose that model as a starting point for building our own model as this model is based on knowledge gathered from quantitative studies of the organelle since the 1960s by dozen of researches. It consists of 58 enzymatic reactions and 117 metabolites, representing the respiratory chain, the TCA cycle, the fatty acid β-oxidation and the inner-membrane transport system. Previously published enzyme kinetics studies in the literature were successfully integrated and packaged into a single large model. All the enzymatic reactions are represented by rate equations found in literature. Of the total of 471 kinetic parameters, 286 are quoted from articles, whereas the rest of the parameters are computationally estimated [21, 36]. A supplementary document describing that computational model can be found at http://www.e-cell.org/ecell/about/supplements/yugi_tomita_supplement.pdf/view. This work offered a perfect starting point to construct a kinetic model for fatty acid metabolism with particular focus on the β-oxidation cycle and the objective to enhance our understanding of various deficiencies of acyl-CoA dehydrogenases.
In order to strike a balance between simplicity and complexity of our simulation model, we extracted the β-oxidation part of the mitochondrial model (reducing complexity), modified and completed it with respect to simulating mitochondrial fatty acid oxidation deficiencies. The β-oxidation cycle together with the metabolite transporting system originally comprised 8 different enzymatic reactions with 5 different reaction mechanisms. The modifications of the original model comprise three central parts that are essential for simulating mitochondrial fatty acid oxidation deficiencies: (i) extension to the oxidation of stearoyl-CoA (C18), arachidonoyl-CoA (C20) and behenoyl-CoA (C22) (ii) input of short, medium and long chain fatty acids entering the β-oxidation cycle (iii) modeling of acyl-CoA dehydrogenase using four enzymes classified by their fatty acid chain length specificity.
There is no evidence that the first three steps of the β-oxidation cycle of stearoyl-CoA (C18), arachidonoyl-CoA (C20) and behenoyl-CoA (C22) are different from the steps of the other acyl-CoAs. We used the same parameters for stearoyl-CoA (C18), arachidonoyl-CoA (C20) and behenoyl-CoA (C22) as well as for the other acyl-CoAs, and explored only the parameters of the oxoacyl-CoA thiolase – the fourth step of the β-oxidation cycle – in dependence on the carbon chain length. However, simulations revealed that the variation of these parameters with regard to carbon chain length had no impact on acyl-CoA concentrations (data are not shown). Therefore, we set the parameters to the same values as for palmitoyl-CoA (C16).
Short and medium chain fatty acids (C4 – C12) were assumed to enter the β-oxidation cycle directly, whereas long and very-long chain fatty acids (C14–C22) were entering the cycle via the carnitine transporting system. The input of short, medium and long chain fatty acids entering the β-oxidation cycle depends on the concentration of the fatty acids in the inter-membrane space. A higher input results in a higher output – the production of acetyl-CoA – as can be seen in Figure 7. We modeled the input as a source with constant levels of acyl CoAs entering the β-oxidation cycle and the output as a sink resulting in a constant level of acetyl CoA. The distribution of the fatty acids in the body depends on several conditions like fatty acid transport conditions, metabolic conditions (e.g., fasting or catabolic stress), ingestion, to name just a few examples. Since we are interested in the accumulation of acyl-CoAs and the formation of acetyl-CoA for various deficiencies of acyl-CoA dehydrogenase and the corresponding dynamic response to moderate increase of palmitoyl-CoA (C16), we estimated the input of the beta-oxidation with the objective to fit and reproduce the experimentally derived acylcarnitine data of MCAD deficiency.
The modeling of acyl-CoA dehydrogenase using four enzymes classified by their fatty acid chain length specificity is based on experimental findings shown by the distribution of the enzyme activity in Figure 2.
We treated the mitochondrial matrix and intermembrane-space free carnitines as well as the intermembrane-space free CoA and acylCoA as fixed parameters in order to guarantee constant input of acylCoA to the beta-oxidation cycle. We did not get any enlarged acylcarnitine pools in all our calculations. If we set the mitochondrial matrix and intermembrane-space free carnitines variable, very small changes of mitochondrial matrix and intermembrane-space free carnitines were found resulting in a little bit smaller flux of acylCoA entering the beta-oxidation cycle. These very small changes did not impact on our results (data not shown). The level of matrix CoA was set high and variation of multiple magnitudes of that level did not impact on our results (data not shown).
The final model consisted of 64 reactions with 91 compounds (36 with fixed values) and 301 parameters. The entire model at different simulation states in SBML format can be found in the Additional files. The users can directly open the SBML files in COPASI  or use other simulation software http://sbml.org, and modify this model of β-oxidation at different disease states.
Starting with initial concentrations, steady-state values were calculated under acyl-CoA dehydrogenase activity conditions of healthy controls. Subsequently, that steady-state of the model was the starting point to calculate steady-state values under mitochondrial fatty acid oxidation deficiencies conditions. These calculations are summarized in simulation A. Results of simulation A were compared and validated with experimental data. Finally, the models obtained in simulation A were used in simulation B where dynamic responses with respect to catabolic stress were calculated.
The initial metabolite concentrations (see Additional file 1) are taken from the literature or set approximately to their Km values of the enzymes . Simulations are performed by numerical integration of the rate equations using the simulation software COPASI 4.2 Build 22 . The acyl-CoA dehydrogenase activity was set according to healthy controls shown in Figure 2B. The new steady-state values of all metabolites were obtained by simulating the concentrations over a one year period (see Additional file 2).
Starting from the steady-state values of healthy controls, the acyl-CoA dehydrogenase activity was changed according to Figure 2B. Again, the new steady-state values of all metabolites for SCADD, MCADD, LCADD and VLCADD were obtained by simulating the concentrations over a one year period (see Additional files 3, 4, 5, 6). Results of these simulations are shown in Figure 3 and 4.
In order to analyze the dynamic behavior of the model, we increased palmitoyl-CoA (C16) in the inter-membrane space by 20%, 30% and 40%. The dynamical behavior of a 20% increase for the control group as well as for the different acyl-CoA dehydrogenase deficiencies are shown in Figure 5, 6. In Table 4 ratios of specific acyl-CoA concentrations before and 30 days after 20%, 30%, and 40% increase of palmitoyl-CoA (C16) are given. Finally, dynamical behavior concerning acetyl-CoA production simulating 20% as well as 40% increase of C16 is shown in Figure 7. We have not found any direct physiological evidence for our chosen 20% to 40% increase of palmitoyl-CoA with regards to catabolic stress. Our choice was first based on an assumption that was subsequently supported by our analysis of the dynamical behavior of the β-oxidation model. The performed simulations reveal that higher increases of C16 do not change the characteristic of the production rate of acetyl-CoA during the first few hours. We are interested in exploring this time period in particular, since rapid progress to coma of patients during fasting occurs within 1–2 hours. Additionally a higher increase of C16 results in higher accumulation of acyl-CoAs as well as increases the time to attain the steady-state of the system.
Validation and limitation
The three central modifications of the original model are based on findings from literature or from performed simulations.
Overall validation was given by relating the calculated variables of the model (the metabolites of the β-oxidation cycle) to experimental available data from two new-born screening programs in Europe and Australia (simulation A). The overall characteristics of the simulated accumulation of acyl-CoA show good agreement with experimental data and findings in the literature (Figure 3 and Figure 4).
A limitation of our work relates to the direct comparison of calculated and measured data. It has to be considered that experimental data of the (isolated) mitochondria are not available and that the available measured data are not only influenced by the respective subsystem (the beta-oxidation cycle), but also may reflect additional effects caused by other subsystems and disease conditions.
Further limitations comprise that only saturated fatty acids were considered and that the β-oxidation of unsaturated fatty acids and odd-numbered chains of carbon were not modeled. Furthermore, we did not include carbon chain length dependencies of the activity of enoyl-CoA hydratase, β-hydroxyacyl-CoA dehydrogenase and 3-ketoacyl-CoA thiolase.
We thank Adelbert Roscher from Dr. von Hauner Children's Hospital, University of Munich, Germany and Enzo Ranieri from the Women's and Children's Hospital, Adelaide, South Australia for providing unlinked anonymous newborn screening data.
- Gregersen N, Bross P, Andresen BS: Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. Molecular pathogenesis and genotype-phenotype relationships. Eur J Biochem. 2004, 271: 470-482. 10.1046/j.1432-1033.2003.03949.xView ArticlePubMedGoogle Scholar
- Furuta S, Miyazawa S, Hashimoto T: Purification and properties of rat liver acyl-CoA dehydrogenases and electron transfer flavoprotein. J Biochem. 1981, 90: 1739-1750.PubMedGoogle Scholar
- Ikeda Y, Dabrowski C, Tanaka K: Separation and properties of five distinct acyl-CoA dehydrogenases from rat liver mitochondria. J Biol Chem. 1983, 258: 1066-1076.PubMedGoogle Scholar
- Ikeda Y, Okamura-Ikeda K, Tanaka K: Purification and characterization of short-chain, medium-chain, and long-chain acyl-CoA dehydrogenases from rat liver mitochondria. Isolation of the holo- and apoenzymes and conversion of the apoenzyme to the holoenzyme. J Biol Chem. 1985, 260: 1311-1325.PubMedGoogle Scholar
- Izai K, Uchida Y, Orii T, Yamamoto S, Hashimoto T: Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acyl-coenzyme A dehydrogenase. J Biol Chem. 1992, 267: 1027-1033.PubMedGoogle Scholar
- Ensenauer R, He M, Willard JM, Goetzman ES, Corydon TJ, Vandahl BB, Mohsen AW, Isaya G, Vockley J: Human acyl-CoA dehydrogenase-9 plays a novel role in the mitochondrial β-oxidation of unsaturated fatty acids. J Biol Chem. 2005, 37: 32309-32316. 10.1074/jbc.M504460200View ArticleGoogle Scholar
- Wanders RJ, Vreken P, den Boer ME, Wijburg FA, van Gennip AH, Ijlst L: Disorders of mitochondrial fatty acyl-CoA beta-oxidation. J Inher Metab Dis. 1999, 22: 442-487. 10.1023/A:1005504223140View ArticlePubMedGoogle Scholar
- Rhead WJ: Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective. J Inherit Metab Dis. 2006, 29: 370-377. 10.1007/s10545-006-0292-1View ArticlePubMedGoogle Scholar
- Stanley CA, Bennett MJ, Mayatepek E: Disorders of fatty acid oxidation. Inborn metabolic diseases, diagnosis and treatment. Edited by: Fernandes J, Saudubray JM, VandenBerghe G. 2006, 150-190. Berlin, SpringerGoogle Scholar
- Sim KG, Hammond J, Wilcken B: Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clin Chim Acta. 2002, 323: 37-58. 10.1016/S0009-8981(02)00182-1View ArticlePubMedGoogle Scholar
- Wilcken B: Recent advances in newborn screening. J Inherit Metab Dis. 2007, 30: 129-133. 10.1007/s10545-007-0538-6View ArticlePubMedGoogle Scholar
- Wilcken B, Wiley V, Hammond J, Carpenter K: Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003, 348: 2304-2312. 10.1056/NEJMoa025225View ArticlePubMedGoogle Scholar
- Baumgartner C, Graber A: Data mining and knowledge discovery in metabolomics. Successes and new directions in data mining. Edited by: Masseglia F, Poncelet P, Teisseire M. 2008, USA, IgI GlobalGoogle Scholar
- Baumgartner C, Böhm C, Baumgartner D: Modelling of classification rules on metabolic patterns including machine learning and expert knowledge. J Biomed Inf. 2005, 38: 89-98. 10.1016/j.jbi.2004.08.009View ArticleGoogle Scholar
- Baumgartner C, Böhm C, Baumgartner D, Marini G, Weinberger K, Olgemöller B, Liebl B, Roscher AA: Supervised machine learning techniques for the classification of metabolic disorders in newborns. Bioinformatics. 2004, 20: 2985-2996. 10.1093/bioinformatics/bth343View ArticlePubMedGoogle Scholar
- Lemberger T: Systems biology in human health and disease. Mol Syst Biol. 2007, 3: 136- 10.1038/msb4100175PubMed CentralView ArticlePubMedGoogle Scholar
- Greef van der J, Martin S, Juhasz P, Adourian A, Plasterer T, Verheij ER, McBurney RN: The art and practise of systems biology in medicine: mapping patterns of relationships. J Proteome Res. 2007, 6: 1540-1559. 10.1021/pr0606530View ArticlePubMedGoogle Scholar
- Greef van der J, Hankemeier T, McBurney RN: Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials?. Pharmacogenomics. 2006, 7: 1087-1094. 10.2217/14622418.104.22.1687View ArticlePubMedGoogle Scholar
- Crampin EJ, Halstead M, Hunter P, Nielsen P, Noble D, Smith N, Tawhai M: Computational physiology and the Physiome Project. Exp Physiol. 2004, 89: 1-26. 10.1113/expphysiol.2003.026740View ArticlePubMedGoogle Scholar
- Nakayama Y, Kinoshita A, Tomita M: Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition. Theor Biol Med Model. 2005, 2: 18- 10.1186/1742-4682-2-18PubMed CentralView ArticlePubMedGoogle Scholar
- Yugi K, Tomita M: A general computational model of mitochondrial metabolism in a whole organelle scale. Bioinformatics. 2004, 20: 1795-1796. 10.1093/bioinformatics/bth125View ArticlePubMedGoogle Scholar
- Ma H, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, Goryanin I: The Edinburgh human metabolic network reconstruction and its functional analysis. Mol Syst Biol. 2007, 3: 135- 10.1038/msb4100177PubMed CentralView ArticlePubMedGoogle Scholar
- Goel G, Chou IC, Voit EO: Biological systems modeling and analysis: a biomolecular technique of the twenty-first century. J Biomol Tech. 2006, 17: 252-269.PubMed CentralPubMedGoogle Scholar
- Roe CR, Ding J: Mitochondria fatty acid oxidation disorders. The metabolic and molecular bases of inherited disease. Edited by: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A. 2007, New York, McGraw-HillGoogle Scholar
- Rashed MS, Rahbeeni Z, Ozand PT: Application of electrospray tandem mass spectrometry to neonatal screening. Semin Perinatol. 1999, 23: 183-193. 10.1016/S0146-0005(99)80050-0View ArticlePubMedGoogle Scholar
- van Hove JL, Zhang W, Kahler SG, Roe CR, Chen YT, Terada N, Chace DH, Iafolla AK, Ding JH, Millington DS: Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood. Am J Hum Genet. 1993, 52: 958-966.PubMed CentralPubMedGoogle Scholar
- Sewell AC, Böhles HJ: Acylcarnitines in intermediary metabolism. Eur J Pediatr. 1995, 154: 871-877. 10.1007/BF01957495View ArticlePubMedGoogle Scholar
- Liebl B, Fingerhut R, Röschinger W, Muntau A, Knerr I, Olgemöller B, Zapf A, Roscher AA: Model project for updating neonatal screening in Bavaria: concept and initial results. Gesundheitswesen. 2000, 62: 189-195. 10.1055/s-2000-10856View ArticlePubMedGoogle Scholar
- Metz MP, Ranieri E, Gerace RL, Priest KR, Luke CG, Chan A: Newborn screening in South Australia: is it universal?. Med J Aust. 2003, 179: 412-415.PubMedGoogle Scholar
- Reis de Assis D, Maria Rde C, Borba Rosa R, Schuck PF, Ribeiro CA, da Costa Ferreira G, Dutra-Filho CS, Terezinha de Siuza Wyse A, Duval Wannmacher CM, Santos Perry ML, Wajner M: Inhibition of energy metabolism in cerebral cortex of young rats by the medium-chain fatty acids accumulating in MCAD deficiency. Brain Res. 2004, 1030: 141-151. 10.1016/j.brainres.2004.10.010View ArticlePubMedGoogle Scholar
- Schuck PF, Ceolato PC, Ferreira GC, Tonin A, Leipnitz G, Dutra-Filho CS, Latini A, Wajner M: Oxidative stress induction by cis-4-decenoic acid: Relevance for MCAD deficiency. Free Radic Res. 2007, 41: 1261-1272. 10.1080/10715760701687109View ArticlePubMedGoogle Scholar
- Rinaldo P, Matern D, Bennett MJ: Fatty acid oxidation disorders. Annu Rev Physiol. 2002, 64: 477-502. 10.1146/annurev.physiol.64.082201.154705View ArticlePubMedGoogle Scholar
- Cox KB, Hamm DA, Millington DS, Matern D, Vockley J, Rinaldo P, Pinkert CA, Rhead WJ, Lindsey JR, Wood PA: Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse. Hum Mol Genet. 2001, 10: 2069-2077. 10.1093/hmg/10.19.2069View ArticlePubMedGoogle Scholar
- Berger PS, Wood PA: Disrupted blastocoele formation reveals a critical developmental role for long-chain acyl-CoA dehydrogenase. Mol Genet Metab. 2004, 82: 266-272. 10.1016/j.ymgme.2004.06.001View ArticlePubMedGoogle Scholar
- Takahashi K, Ishikawa N, Sadamoto Y, Sasamoto H, Ohta S, Shiozawa A, Miyoshi F, Naito Y, Nakayama Y, Tomita M: E-Cell 2: multi-platform E-Cell simulation system. Bioinformatics. 2003, 19: 1727-1729. 10.1093/bioinformatics/btg221View ArticlePubMedGoogle Scholar
- Yugi K, Tomita M: Quantitative modelling of mitochondrial energy metabolism using E-cell simulation environment. Genome Informatics. 2000, 11: 456-457.Google Scholar
- Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N, Singhal M, Xu L, Mendes P, Kummer U: COPASI – a COmplex PAthway SImulator. Bioinformatics. 2006, 22: 3067-3074. 10.1093/bioinformatics/btl485View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.